Drug intelligence / Profile preview

MGD020

Development stage: Phase 1
Lead developer: MacroGenics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MGD020 is a bispecific DART (Dual-Affinity Re-Targeting) molecule developed by MacroGenics. It is designed to bind both CD3 on T cells and the gp41 subunit of the HIV-1 envelope. By engaging these targets, MGD020 redirects CD3+ T lymphocytes to recognize and kill HIV-1-infected CD4+ T cells. It is being developed as a potential immunotherapeutic agent for people with HIV-1 infection who are on antiretroviral therapy. The drug is currently in phase 1 clinical trials, both as a single agent and in combination with another DART molecule, MGD014, which targets CD3 and the gp120 subunit of HIV-1 envelope.

Targets

gp41 (Human immunodeficiency virus type 1 glycoprotein 41)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on MGD020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGD020.

Explore the full profile